NCT06176040View on ClinicalTrials.gov

A Study of TAVO101 in Atopic Dermatitis Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

March 15, 2025

Study Completion Date

June 15, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

TAVO101

TAVO101 IV Infusion.

Trial Locations (2)

3052

Royal Melbourne Hospital, Parkville

Unknown

Optimal Clinical Trials, Auckland

Sponsors
All Listed Sponsors
lead

Tavotek Biotherapeutics

INDUSTRY

NCT06176040 - A Study of TAVO101 in Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter